Author Archives: Erica Carnevale
Top categories
Mammography image quality
![](https://www.volparahealth.com/app/uploads/2024/07/Mammography-Positioning-Improvement_350.jpg)
19 Jul 2024
Time to modernize: Integrating AI into the ACR Mammography Positioning Improvement Initiative
Breast cancer, Volumetric breast density
![](https://www.volparahealth.com/app/uploads/2022/05/Research-Brief-resized.png)
17 Jul 2024
New insights into high-risk MRI screening re-attendance
News
![](https://www.volparahealth.com/app/uploads/2022/01/Volpara-General-Positioning-Training.png)
17 Jul 2024
Volpara Health Enhances Executive Team to Focus on Customer Success and Growth
Breast cancer
![](https://www.volparahealth.com/app/uploads/2024/06/BINZ_Volpara_Density.png)
18 Jun 2024
Turning the Tide on Breast Cancer Inequities in New Zealand: A Call to Action
Breast cancer, News
![](https://www.volparahealth.com/app/uploads/2024/05/social-graphic-conquering-cancer-together-e1716344161183.jpg)
21 May 2024
Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care
Mammography image quality, News
![](https://www.volparahealth.com/app/uploads/2024/05/ASMIR1.png)
10 May 2024
Diagnostic Imaging for Women Enhances Mammography Quality with AI: Results Presented at ASMIRT 2024
Mammography image quality, News
![](https://www.volparahealth.com/app/uploads/2023/05/SBI-product-PR.png)
12 Apr 2024
Volpara Launches MQSA Compliance Software at the Society for Breast Imaging Symposium
Breast cancer, Mammography image quality
![](https://www.volparahealth.com/app/uploads/2022/08/Analytics-and-EQUIP-reports.png)
31 Mar 2024
AI to help your mammography MQSA audit…yes, really
News
![](https://www.volparahealth.com/app/uploads/2023/10/POTYA_HaLS-1200x627-1-min.jpg)
27 Jun 2023
Volpara recognized as the winner of 2023 Microsoft Healthcare & Life Sciences Partner of the Year
Lung cancer screening, News
![](https://www.volparahealth.com/app/uploads/2021/09/Reveal-Dx-logo.png)
21 Sep 2022
RevealDx’s precision medicine software for lung nodule risk analysis receives regulatory clearance in Australia and New Zealand